Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC 3 and DU 145

Because of unsatisfactory treatment options for prostate cancer (CaP) there is a need to develop novel preventive approaches for this malignancy. One such strategy is through chemoprevention by the use of non-toxic dietary substances and botanical products. We have shown previously that panduratin A isolated from the extract of Kaempferia pandurata (Zingiberaceae) is a strong inhibitor of cyclooxygenase-2 in RAW264.7 cells and induces apoptosis in HT-29 cells. In the present study, we provide evidence that panduratin A treatment to androgenindependent human CaP cells PC3 and DU145 result in a time and dose-dependent inhibition of cell growth with an IC50 of 13.5–14 mM and no to little effect on normal human prostate epithelial cells. To define the mechanism of these anti-proliferative effects of panduratin A, we determined its effect on critical molecular events known to regulate the cell cycle and the apoptotic machinery. Annexin V/propidium iodide staining provided the evidence for the induction of apoptosis which was further confirmed by the observation of cleavage of poly (ADPribose) polymerase and degradation of acinus. Panduratin A treatment to cells was found to result in inhibition of procaspases 9, 8, 6 and 3 with significant increase in the ratio of Bax:Bcl-2, suggesting the involvement of a mitochondrial-dependent apoptotic pathway. Panduratin A-mediated apoptosis was accompanied with upregulation of Fas death receptor and TNF-related apoptosisinducing ligand (TRAIL). Furthermore, cell cycle analysis using flow cytometry showed that panduratin A treatment of cells resulted in a G2/M arrest in a dose-dependent manner. The immunoblot analysis data revealed that in both cell lines panduratin A treatment resulted in a dosedependent (i) induction of p21 and p27, (ii) downregulation of cdks 2, 4 and 6 and (iii) decrease in cyclins D1 and E. These findings suggest that panduratin A may be an effective chemopreventive or therapeutic agent against CaP.

[1]  H. Mukhtar,et al.  Induction of apoptosis by Panduratin A isolated from Kaempferia pandurata in human colon cancer HT-29 cells. , 2005, Planta medica.

[2]  Z. Darżynkiewicz,et al.  Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. , 2004, Biochemical and biophysical research communications.

[3]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[4]  Wei Hu,et al.  Anticancer therapy targeting the apoptotic pathway. , 2003, The Lancet. Oncology.

[5]  Jae-Kwan Hwang,et al.  In Vitro Anti-Inflammatory Activity of Panduratin A Isolated from Kaempferia pandurata in RAW264.7 Cells , 2003, Planta medica.

[6]  G. Kroemer,et al.  Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe , 2002, Cell Death and Differentiation.

[7]  R. Agarwal,et al.  Phytochemicals as Cell Cycle Modulators A Less Toxic Approach in Halting Human Cancers , 2002, Cell cycle.

[8]  E. Solary,et al.  CELL DEATH PATHWAYS AS TARGETS FOR ANTICANCER DRUGS , 2002 .

[9]  P. Tuchinda,et al.  Anti-inflammatory cyclohexenyl chalcone derivatives in Boesenbergia pandurata. , 2002, Phytochemistry.

[10]  M.-H. Lee,et al.  Contributions in the domain of cancer research: Review¶Negative regulators of cyclin-dependent kinases and their roles in cancers , 2001, Cellular and Molecular Life Sciences CMLS.

[11]  R. DiPaola,et al.  Targeting apoptosis in prostate cancer. , 2001, Hematology/oncology clinics of North America.

[12]  H. Shinmoto,et al.  Structural analysis of a novel antimutagenic compound, 4-Hydroxypanduratin A, and the antimutagenic activity of flavonoids in a Thai spice, fingerroot (Boesenbergia pandurata Schult.) against mutagenic heterocyclic amines. , 2001, Journal of agricultural and food chemistry.

[13]  Yigong Shi,et al.  A structural view of mitochondria-mediated apoptosis , 2001, Nature Structural Biology.

[14]  G. Stark,et al.  Regulation of the G2/M transition by p53 , 2001, Oncogene.

[15]  G. Kroemer,et al.  Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis , 2001, Oncogene.

[16]  A. Taraphdar,et al.  NATURAL PRODUCTS AS INDUCERS OF APOPTOSIS: IMPLICATION FOR CANCER THERAPY AND PREVENTION , 2001 .

[17]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[18]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[19]  B. Davidson,et al.  Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis1 , 2000, The Journal of Immunology.

[20]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[21]  Edward A. Sausville,et al.  The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01* , 2000, The Journal of Biological Chemistry.

[22]  L. Tsao,et al.  Synthesis and Anti‐inflammatory Effect of Chalcones , 2000, The Journal of pharmacy and pharmacology.

[23]  J. Martinou,et al.  Bid Induces the Oligomerization and Insertion of Bax into the Outer Mitochondrial Membrane , 2000, Molecular and Cellular Biology.

[24]  A. Saraste,et al.  Morphologic and biochemical hallmarks of apoptosis. , 2000, Cardiovascular research.

[25]  Yinxiao－Ming.  Signal transduction mediated by Bid,a pro—death Bcl—2 family proteins,connects the death receptor and mitochondria apoptosis pathways , 2000 .

[26]  A. Belldegrun,et al.  Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature , 1999, Prostate Cancer and Prostatic Diseases.

[27]  G R Howe,et al.  Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. , 1999, Nutrition and cancer.

[28]  K. Vousden,et al.  Mechanisms of p53-mediated apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.

[29]  Y. Surh,et al.  Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol. , 1998, Cancer letters.

[30]  M. Peter,et al.  Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. , 1998, Current opinion in immunology.

[31]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[32]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[33]  P. Hamilton,et al.  Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. , 1998, British Journal of Cancer.

[34]  R. Agarwal,et al.  Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. , 1997, Journal of the National Cancer Institute.

[35]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[36]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[37]  S. Reed,et al.  Accumulation of p 21 Cip 1 at the Onset of Mitosis : a Role at the G 2 / M-Phase Transition , 1997 .

[38]  T. Yasumoto,et al.  Suitability of the MTT-based cytotoxicity assay to detect okadaic acid contamination of mussels. , 1996, Toxicon : official journal of the International Society on Toxinology.

[39]  C. la Vecchia,et al.  Fruit and vegetable consumption and cancer risk in a Mediterranean population. , 1995, The American journal of clinical nutrition.

[40]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[41]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[42]  M. Kirschner,et al.  Mitosis in transition , 1994, Cell.

[43]  L. Hengst,et al.  A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells , 1994, Molecular and cellular biology.

[44]  James M. Roberts,et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.

[45]  J. Larsen,et al.  Cancer-protective factors in fruits and vegetables: biochemical and biological background. , 1993, Pharmacology & toxicology.

[46]  J. Gerhart,et al.  Cell cycle tyrosine phosphorylation of p34cdc2 and a microtubule-associated protein kinase homolog in Xenopus oocytes and eggs , 1991, Molecular and cellular biology.

[47]  E. Nigg,et al.  Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites. , 1991, The EMBO journal.

[48]  V. Reutrakul,et al.  (1'RS,2'SR,6'RS)-(2,6-dihydroxy-4-methoxyphenyl)-methanone (panduratin A)--a constituent of the red rhizomes of a variety of Boesenbergia pandurata , 1984 .